The idea of altering amino acid metabolism and energy stress in the microenvironment through metabolic reprogramming at the tumor site to inhibit mTOR activation is also emerging as a new research hotspot for CCA therapeutic regimens. Here, MTOR is linked to cholangiocarcinoma.